Work

Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Year: 2021

Type: erratum

Source: Nature Medicine

DOI: 10.1038/s41591-021-01516-1

Authors: Toni K. Choueiri, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard J. Appleman, Sanjay Thamake, Rodolfo F. Perini, Naseem J. Zojwalla, Eric Jonasch

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Sarah Cannon, Tennessee Oncology, South Texas Accelerated Research Therapeutics, Fox Chase Cancer Center, University of Miami, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, University of Pittsburgh Medical Center, Merck & Co., Inc., Rahway, NJ, USA (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Defense, Dana-Farber/Harvard Cancer Center, National Cancer Institute

Awards: G1273380608, G6261537273, G8694494015

OpenAlex ID: W3195528627

Cites:

Cited by: 5

Related to: 10